文献速递头颈部肿瘤放疗

同期放化疗期间嗜酸性粒细胞动态与Ⅱ-Ⅳa期鼻咽癌患者临床结局相关:一项大型队列研究结果

Eosinophil dynamics during chemo-radiotherapy correlate to clinical outcome in stage Ⅱ-Ⅳa nasopharyngeal carcinoma patients: Results from a large cohort study.
PubMed 文献 · Radiother Oncol · 2023-09-01

该大型队列研究纳入1225例Ⅱ-Ⅳa期鼻咽癌患者,采用模糊C均值算法评估根治性放疗期间循环嗜酸性粒细胞计数的纵向趋势,并按治疗期间动态类型与治疗结束时计数值的交互作用定义三个嗜酸性粒细胞耗竭等级。结果显示三个耗竭等级显著分层无进展生存、总生存和无远处转移生存,治疗前高嗜酸性粒细胞计数是严重耗竭等级的最强保护因素,但高治疗前计数患者从同期放化疗中获益减弱。

要点

  • 三个嗜酸性粒细胞耗竭等级显著分层鼻咽癌患者无进展生存、总生存和无远处转移生存。
  • 治疗前高循环嗜酸性粒细胞计数是严重耗竭等级(G0 vs G2,HR=0.20;G1 vs G2,HR=0.14)的最强保护因素。
  • 与单纯放疗相比,治疗前高嗜酸性粒细胞计数患者从同期放化疗中的获益减弱。

核心结论

  • 鼻咽癌患者治疗后循环嗜酸性粒细胞计数下降可能有助于临床评估标准治疗的预后。

研究设计与样本

  • 大型队列研究,纳入1225例Ⅱ-Ⅳa期鼻咽癌患者,采用模糊C均值算法评估根治性放疗期间循环嗜酸性粒细胞计数的纵向趋势。
  • 采用Kaplan-Meier分析和Cox比例风险模型评估嗜酸性粒细胞耗竭等级对生存的不良预后影响及风险比。
  • 在Cox回归模型框架内使用风险比评估治疗前循环嗜酸性粒细胞计数与同期放化疗对结局的交互效应。

主要发现

  • 与G0相比,G1组无进展生存、总生存和无远处转移生存的风险分别为1.57倍(P=0.001)、1.69倍(P=0.007)和1.51倍(P=0.019)。
  • 与G0相比,G2组无进展生存、总生存和无远处转移生存的风险分别为2.4倍(P<0.001)、2.76倍(P<0.001)和2.31倍(P<0.001)。
  • 治疗前高循环嗜酸性粒细胞计数是严重耗竭等级的最强保护因素:G0 vs G2的HR=0.20(P=0.005),G1 vs G2的HR=0.14(P<0.001)。
  • 与单纯放疗相比,治疗前高循环嗜酸性粒细胞计数患者从同期放化疗中的获益减弱。

临床怎么用

  • 作者认为,鼻咽癌患者治疗后循环嗜酸性粒细胞计数下降可能有助于临床评估标准治疗的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We investigated the dynamics of eosinophil depletion during definitive concurrent chemo-radiotherapy (CCRT) and their association with the prognosis of stage Ⅱ-Ⅳa nasopharyngeal carcinoma (NPC) patients. MATERIALS AND METHODS: Fuzzy C-means algorithm (FCMA) assessed longitudinal trends in circulating eosinophil counts (CECs) of 1225 patients throughout the period of radical radiotherapy. The prognostic impact on patients' survival was evaluated with Kaplan-Meier analysis and Cox proportional risk model was used to determine the hazard ratio for adverse prognostic effects in grades of eosinophil depletion. The interactive effect of pre-treatment CECs and CCRT on outcomes was evaluated using HRs within the framework of Cox regression models. RESULTS: Three grades of eosinophil depletion, as defined by the interaction between dynamic types of CECs in the period of treatment and the value of CECs at the termination of treatment, significantly stratified the poor prognosis in terms of progression-free survival (PFS), overall survival (OS), and distant metastasis-free survival (DMFS) [1.57-fold (P = 0.001), 1.69-fold (P = 0.007), and 1.51-fold (P = 0.019) for G1, 2.4-fold (P < 0.001), 2.76-fold (P < 0.001), and 2.31-fold (P < 0.001) for G2, as compared with G0]. Furthermore, high levels of pre-treatment CECs acted as the strongest protective factor against severe depletion grade (G0 vs. G2, HR = 0.20, P = 0.005; G1 vs. G2, HR = 0.14, P < 0.001). However, compared with radiotherapy alone, the benefit from CCRT was attenuated in patients with high pre-treatment CECs. CONCLUSIONS: CECs reduction after treatment in patients with NPC may be helpful in the clinical setting to aid in assessing the prognosis for standard treatment of NPC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Li D, Yang LN, Lin JY, et al. Eosinophil dynamics during chemo-radiotherapy correlate to clinical outcome in stage Ⅱ-Ⅳa nasopharyngeal carcinoma patients: Results from a large cohort study. Radiother Oncol. 2023. PMID: 37660752. doi:10.1016/j.radonc.2023.109900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。